The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
Yale inventors have designed, synthesized, and tested a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of wildtype and, more importantly, drug resistant mutant HIV-1 strains.
Efficient use of an in vitro produced chimeric mRNA and other modulator RNAs to create lymphocytes with high levels of specific cytotoxicity against chosen targets.
Glaucoma is the second leading cause of blindness in the world, and the risk for developing the disease increases with age. It is associated with a rise in intraocular pressure (IOP), the reduction of which can usually preserve vision. While effective IOP-lowering medications are available, they require continuous administration, up to several times per day in some cases. Non-compliance with glaucoma medications is very high among elderly patients, with frequent administration requirements strongly associated with nonadherence. This novel treatment addresses the large and growing compliance issue with a sustained delivery timolol maleate injection. With the possibility of administration once every few months at routine doctor's visits, daily compliance is negated.
The present invention relates to the risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this invention relates to the detection of certain polymorphism in the promoter region of the MIF gene to determine the risk, detect, diagnose, or prognosticate prostate cancer. Applicants have discovered that the presence of a -173C and/or -749 (CATT).sub.7 or more repeat predispose an individual to prostate cancer.
The recent discovery of a role for SEMA 7A in fibrosis using mouse models provides a new therapeutic target for the treatment of fibrosis in lung disease and may be suitable for the treatment of other fibrotic diseases.
The invention includes methods of preventing and reversing prefrontal cortical decline in normal aged subjects by providing a protein kinase C inhibitor to the subject. The protein kinase C inhibitor can be a phenanthridinium alkaloids or other closely related compound. The inventors have found that when such compounds are administered to normal aged subjects the cognitive performance, including including performance in tasks that utilizing working memory, of the subjects improves.
ROCK1, or Rho kinase, is a protein kinase activated by Rho that plays a signaling role in cell morphology, transformation, motility, focal adhesion, and cytokinesis. Inhibition of this pathway may prevent tumor cell motility and metastasis. Novel small-molecule inhibitors of ROCK1 have been synthesized and assayed for activity in vitro, and are candidates as anti-cancer drugs.
Adoptive T cell transfer, involving the ex vivo expansion of T lymphocytes, is a viable therapeutic approach for both infectious diseases and cancer, with demonstrated efficacy in treating melanoma, Epstein-Barr virus, and HIV-related infections. However, T cell transfer by clonal expansion is not clinically feasible as it does not consistently generate therapeutic quantities of T cells. Efforts to develop a reproducible "off-the-shelf" means of stimulating and expanding T cells in vitro have focused on bead-based systems. This novel approach involves single walled carbon nanotubes (SWNT) coupled to anti-CD3 antibodies, a known stimulant for T-cell proliferation. SWNTs have a much higher surface area to volume ratio than previous artificial antigen-presenting cells (aAPCs), which facilitates the high density clusters of T cell antigen receptors that are critical for T-cell activation. Anti-CD3 antibodies adsorbed onto SWNT bundles activate T-cells at antibody concentrations at least an order of magnitude less than antibody alone. Furthermore, similar activation is not achieved with other high surface area materials such as activated carbon, polystyrene nanoparticles, and buckyballs. This novel method thus utilizes the unique properties of SWNTs for enhanced stimuli presentation.
Yale scientists have discovered that the level of IL-18 and its downstream targets were increased in patients with COPD, as well as in the lungs of smokers. Furthermore, it was found that treating mice with antibody against IL-18Rα significantly decreased Cigarette Smoke (CS) - induced inflammation. IL-18 signaling contributes to the pathogenesis of CS-induced emphysema, pulmonary inflammation and apoptosis. Therefore, the levels of circulating IL-18 represent a readily accessible biomarker for the diagnosis of COPD, and blocking IL-18Rα would be an effective therapy against COPD.